View Older Stories View More Recent Stories

Feb 10, 2025 07:10AM Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
Feb 10, 2025 07:06AM Cantor Fitzgerald Reiterates Neutral Rating on GlobalFoundries Inc. (GFS)
Feb 10, 2025 07:04AM Proto Labs (PRLB) PT Raised to $50 at Cantor Fitzgerald
Feb 10, 2025 07:02AM Cantor Fitzgerald reiterates Western Digital Corp. (WDC) at Overweight
Feb 7, 2025 04:05PM Rumble Closes $775 Million Strategic Investment from Tether and Related Tender Offer
Feb 7, 2025 08:15AM Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
Feb 7, 2025 07:41AM Cantor Fitzgerald Reiterates Neutral Rating on ViaSat (VSAT)
Feb 7, 2025 07:38AM Cantor Fitzgerald raises Fortinet (FTNFT) price target to $115
Feb 7, 2025 07:34AM Cantor Fitzgerald Reiterates Overweight Rating on Onto Innovation Inc. (ONTO)
Feb 7, 2025 07:32AM Cloudflare Inc. (NET) PT Raised to $149 at Cantor Fitzgerald
Feb 7, 2025 07:07AM Expedia (EXPE) PT Raised to $210 at Cantor Fitzgerald
Feb 7, 2025 07:04AM Cantor Fitzgerald Reiterates Overweight Rating on Amazon.com (AMZN)
Feb 7, 2025 06:33AM Cantor Fitzgerald Reiterates Overweight Rating on Amazon.com (AMZN)
Feb 7, 2025 06:12AM Form POS AM Cantor Fitzgerald Income
Feb 7, 2025 05:36AM Pinterest Inc (PINS) PT Raised to $48 at Cantor Fitzgerald
Feb 6, 2025 04:17PM Cantor Fitzgerald Starts Amentum (AMTM) at Neutral (correction)
Feb 6, 2025 08:42AM Cantor Fitzgerald Starts AST Spacemobile (ASTS) at Overweight
Feb 6, 2025 06:33AM Strategy (MSTR) PT Raised to $619 at Cantor Fitzgerald
Feb 5, 2025 04:01PM Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
Feb 5, 2025 02:00PM BigBear.ai Holdings (BBAI) PT Raised to $8 at Cantor Fitzgerald
Feb 5, 2025 10:33AM US Senate panel advances Cantor Fitzgerald's Lutnick for Commerce Department chief
Feb 5, 2025 10:05AM Cantor Fitzgerald Reiterates Overweight Rating on Skye Bioscience (SKYE)
Feb 5, 2025 10:04AM Cantor Fitzgerald Reiterates Overweight Rating on Centene (CNC)
Feb 5, 2025 10:03AM Amgen (AMGN) PT Lowered to $340 at Cantor Fitzgerald
Feb 5, 2025 10:00AM CVRx Inc (CVRX) PT Lowered to $20 at Cantor Fitzgerald
Feb 5, 2025 09:59AM Cantor Fitzgerald Reiterates Overweight Rating on Hut 8 Mining Corp. (HUT)
Feb 5, 2025 09:58AM Cantor Fitzgerald Reiterates Overweight Rating on Varonis Systems (VRNS)
Feb 5, 2025 09:57AM Cantor Fitzgerald Reiterates Overweight Rating on AMD (AMD)
Feb 5, 2025 09:56AM Alphabet (GOOGL) PT Lowered to $200 at Cantor Fitzgerald
Feb 5, 2025 09:55AM Cantor Fitzgerald Reiterates Neutral Rating on Snap Inc (SNAP)
Feb 5, 2025 09:19AM Spotify (SPOT) PT Raised to $600 at Cantor Fitzgerald
Feb 5, 2025 09:18AM Biogen (BIIB) PT Lowered to $206 at Cantor Fitzgerald
Feb 5, 2025 08:32AM Rumble (RUM) reveal results of tender offer
Feb 5, 2025 08:30AM Rumble Announces Final Results of its Tender Offer
Feb 5, 2025 08:23AM EyePoint Pharmaceuticals' (EYPT) decline "makes no sense", says Cantor Fitzgerald
Feb 4, 2025 08:52PM GH Research Announces Pricing of $150 Million Public Offering
Feb 4, 2025 09:46AM 4Q24 Service Bureau Survey - Cantor Fitzgerald
Feb 4, 2025 09:43AM Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Cantor Fitzgerald
Feb 4, 2025 09:40AM Cantor Fitzgerald Reiterates Overweight Rating on NXP Semiconductors NV (NXPI)
Feb 4, 2025 09:38AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)
Feb 4, 2025 09:36AM Cipher Mining (CIFR) PT Lowered to $10 at Cantor Fitzgerald
Feb 4, 2025 06:01AM Fortinet (FTNT) PT Raised to $110 at Cantor Fitzgerald
Feb 4, 2025 02:27AM Palantir Technologies Inc. (PLTR) PT Raised to $98 at Cantor Fitzgerald
Feb 3, 2025 04:03PM GH Research (GHRS) Announces Proposed Public Offering
Feb 3, 2025 04:03PM GH Research Announces Proposed Public Offering
Feb 3, 2025 09:00AM Regan Capital Announces Fee Reduction for Regan Total Return Income Fund (RCIRX)
Feb 3, 2025 08:00AM 89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Feb 3, 2025 07:30AM Vanda Pharmaceuticals (VNDA) and Anaptys (ANAB) Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab
Feb 3, 2025 07:30AM Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Feb 3, 2025 07:14AM Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY)
View More Recent Stories View Older Stories